June 3, 2020
Pierre Fabre Receives European Approval for BRAFTOVI® (encorafenib) in Combination With Cetuximab for the Treatment of Adult Patients With BRAFV600E-Mutant Metastatic Colorectal Cancer
– European approval is based on the Phase 3 BEACON CRC trial that demonstrated a significant improvement in overall survival…